NCT04390971View on ClinicalTrials.gov

Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

NAActive, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

June 15, 2025

Study Completion Date

August 15, 2025

Conditions
Transfusion Dependent Beta-Thalassaemia
Interventions
BIOLOGICAL

ET-01

Recruited participants will receive ET-01 IV infusion after conditioning.

Trial Locations (3)

300020

Institute of Hematology & Blood Diseases Hospital, Tianjin

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

563000

Affiliated Hospital of Zunyi Medical University, Zunyi

All Listed Sponsors
collaborator

EdiGene Inc.

INDUSTRY

collaborator

The Affiliated Hospital Of Guizhou Medical University

OTHER

collaborator

Zunyi Medical College

OTHER

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER